AlphAIAlphAI — Financial news for AI agents
ibtimes.com.auSEP 302 min read

ImmunityBio Stock Soars 11% as Anktiva Momentum and FDA Catalyst Hopes Fuel Rally in Soon-Shiong's Biotech

ImmunityBio Inc. shares rose 11.44% to $9.84 on Wednesday, driven by investor optimism around its bladder cancer drug Anktiva and an upcoming FDA decision. The company reported record Q2 2026 revenue of $50.7M, up 92% YoY, but posted a loss of 22 cents per share. Anktiva's expanded use and international approvals are key growth drivers.

Original reporting
ibtimes.com.au
Published Sep 30, 2026, 3:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 4:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ImmunityBio Stock Soars 11% as Anktiva Momentum and FDA Catalyst Hopes Fuel Rally in Soon-Shiong's Biotech — source image
Source · ibtimes.com.au
Decision brief

The 30-second read

High
01

Why it matters

The earnings surprise and upgrade sparked an 11% intraday rally, suggesting momentum may continue ahead of the FDA decision.

02

Market read

The article provides fresh earnings data and a catalyst upgrade, offering a clear short‑term trading opportunity.

03

What to watch

Potential regulatory risk from FDA warning letters could temper upside despite earnings beat.

Relevance 7/10Novelty 8/10Timing: intraday today

Background

ImmunityBio reported record Q2 product revenue and an earnings miss on EPS, while analysts upgraded the stock. The company also has an FDA decision pending for label expansion in early 2027.

Market effects

Sector

Positive for biotech sector as a peer demonstrates strong immunotherapy sales growth.

Regional

U.S. biotech stocks may see modest gains following the surprise earnings beat.

Global

Limited to investors tracking FDA pipeline developments and immunotherapy markets.

Counterpoint

What could challenge this read

Short sellers may view the high short interest as a risk if the FDA decision disappoints.

Key entities

  • company
    ImmunityBio Inc.

    Nasdaq-listed biotech developing Anktiva immunotherapy.

  • analyst
    Jefferies

    Upgraded ImmunityBio, contributing to price rise.

Read at source← All news

Related articles

SEP 14
$IBRXMed

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

ImmunityBio (IBRX) shares rose 6% after Nant Capital, led by IBRX founder Soon-Shiong, invested $11.3M in PDS Biotech (PDSB), with an option to license PDS0101. PDSB shares surged 35%. The deal ties Soon-Shiong to another immunotherapy platform, extending his cytokine and cancer-vaccine strategy. Proceeds will support PDSB's debt repayment and late-stage development.

newsable.asianetnews.com2 min
SEP 5
$IBRXMedAI 8/10

IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study

ImmunityBio (IBRX) shares are up 9% this week, despite a Q1 net loss of $632.8M and a 7% drop post-earnings. The company's founder highlighted a decade-old study showing safety and efficacy of NK-92 cells, and plans for a new Anktiva combination trial. Anktiva saw 168% revenue growth and is now available in Saudi Arabia. The FDA is reviewing Anktiva's supplemental application, with a decision expected soon.

stocktwits.com3 min
AUG 23
$SLSHighAI 8/10

SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology

Moderna (MRNA) and Merck (MRK) reported positive Phase 3 trial results for their cancer vaccine, Intismeran Autogene, boosting shares. Analysts raised sales forecasts and approval probabilities. Sellas Life Sciences (SLS) and ImmunityBio (IBRX) are also in focus due to their oncology work. MRNA surged 177%, MRK gained 13%, and other related stocks saw significant moves.

stocktwits.com2 min